目的观察双相躁狂患者血浆中微小RNA-134(micro RNA-134)及LIM激酶-1(LIMK-1)m RNA的表达水平与双相躁狂之间的关系。方法 105例双相躁狂患者作为患者组,100例与患者组在年龄和性别上匹配的健康志愿者作为对照组,患者组常规应用情绪稳...目的观察双相躁狂患者血浆中微小RNA-134(micro RNA-134)及LIM激酶-1(LIMK-1)m RNA的表达水平与双相躁狂之间的关系。方法 105例双相躁狂患者作为患者组,100例与患者组在年龄和性别上匹配的健康志愿者作为对照组,患者组常规应用情绪稳定剂治疗1个月。患者组于入组时和治疗1个月时、对照组于入组时分别评定Bech-Rafaelsen躁狂量表(BRMS)评分表并收集血浆,采用实时荧光定量聚合酶链式反应(PCR)技术检测血浆micro RNA-134及LIMK-1 m RNA的表达水平,最后对检测结果及BRMS评分进行统计分析。结果治疗前,患者组血浆micro RNA-134及LIMK-1 m RNA表达水平分别为(1.17±0.02)、(0.37±0.02)显著低于对照组的(1.46±0.04)、(0.46±0.01),差异有统计学意义(P<0.05);治疗1个月后,患者组血浆micro RNA-134、LIMK-1 m RNA表达水平分别为(1.36±0.07)、(0.52±0.01)较治疗前显著升高,差异有统计学意义(P<0.05)。患者组治疗前及治疗后血浆micro RNA-134表达水平与BRMS评分之间均存在负相关(r=-0.48、-0.39,P<0.05)。结论血浆micro RNA-134、LIMK-1 m RNA的表达水平和双相障碍躁狂发作有关,有可能作为双相躁狂的生物标记物。展开更多
目的:观察百令胶囊联合达格列净治疗糖尿病肾病疗效及对Caspase-1mRNA、NLRP3炎症小体水平的影响。方法:采用随机数字表法将80例糖尿病肾病患者分成观察组和对照组。对照组予达格列净治疗,观察组同时联合百令胶囊治疗。经连续治疗3个月...目的:观察百令胶囊联合达格列净治疗糖尿病肾病疗效及对Caspase-1mRNA、NLRP3炎症小体水平的影响。方法:采用随机数字表法将80例糖尿病肾病患者分成观察组和对照组。对照组予达格列净治疗,观察组同时联合百令胶囊治疗。经连续治疗3个月,比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、肾功能指标[肾小球滤过率(eGFR)、血肌酐(Scr)、24 h尿微量白蛋白]、NLRP3炎性小体、半胱氨酸蛋白酶1(Caspase-1)mRNA、炎性因子[肿瘤坏死因子(TNF-α)、白细胞介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)]水平变化,统计两组治疗总有效率,评价治疗安全性。结果:治疗后,两组FPG、2 h PG、HbA1c水平,Scr、eGFR、24 h尿微量白蛋白水平,Caspase-1mRNA、NLRP3炎症小体表达水平,TNF-α、IL-1β、hs-CRP水平均明显低于治疗前(P<0.05),且观察组治疗以上指标水平均低于对照组(P<0.05);观察组总有效率为92.5%,优于对照组(75.0%)(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:百令胶囊联合达格列净治疗糖尿病肾病疗效显著,能够有效控制血糖水平,减少24 h尿蛋白,改善患者肾功能,治疗机制可能与抑制炎症反应、降低NLRP3炎症小体水平有关。展开更多
Objective The initiation and progression of lung carcinomas are critically regulated by long non-coding RNAs(lncRNAs).However,the role of lncRNAs in the pathways causing lung cancer remains unknown.Methods Cell morpho...Objective The initiation and progression of lung carcinomas are critically regulated by long non-coding RNAs(lncRNAs).However,the role of lncRNAs in the pathways causing lung cancer remains unknown.Methods Cell morphology was regularly observed using an inverted phase-contrast microscope.Cell viability was assessed using CCK-8 according to the manufacturer’s instructions.Total RNA was retrotranscribed from each specimen using the RNAiso Plus Kit.The RT-PCR data were calculated using the Ct approach for comparison.Flow cytometric analyses were prepared by Click-iT™Plus TUNEL Assay for In Situ apoptosis detection,with Alexa Fluor^(TM)594 dye,as instructed.RNA immunoprecipitation assays were used to determine RNA concentration.Results Activated natural killer cells repeat and PH domain-containing protein 2 antisense RNA 1(AGAP2-AS1)levels in cancerous tissues were significantly correlated with cancerous tumor node metastasis(TNM)stage,with cancerous AGAP2-AS1 levels being higher in cancerous tissues than healthy tissues.Patients withelevated AGAP2-AS1 levels had considerably worse outcomes than those with reduced AGAP2-AS1 levels,regardless of the progression-free or overall survival.Functionally,AGAP2-AS1 downregulation represseslung cancer cell growth.AGAP2-AS1 elimination induces erastin-mediated ferroptosis in lung cancer cells.However,the ferritin inhibitor FERSINT-1 negated this result,whereas ERASTIN induced lung cancer cellmortality.After AGAP2-AS1 silencing,erastin-treated lung cancer cells showed a remarkable decrease inGSH levels.These results indicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via Recombinant Insulin Like Growth Factor Binding Protein 2(IGF BP2).Patients with elevated AGAP2-AS1 had considerably worse outcomes.Down-regulating AGAP2-AS1 was able to repress lung cancer cell growth and induce greater Erastin-mediated ferroptosis.Lungcancer cells treated with Erastin exhibited a remarkable decrease inglutathione(GSH)levels.The mechanical findingsindicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via the IGF2BP2.Conclusion We identified a novel effect of AGAP2-AS1 on TNM staging and the prognosis of patientswith lungcancer by modulating SLC7A11 mRNA stability and ferroptosis.展开更多
文摘目的观察双相躁狂患者血浆中微小RNA-134(micro RNA-134)及LIM激酶-1(LIMK-1)m RNA的表达水平与双相躁狂之间的关系。方法 105例双相躁狂患者作为患者组,100例与患者组在年龄和性别上匹配的健康志愿者作为对照组,患者组常规应用情绪稳定剂治疗1个月。患者组于入组时和治疗1个月时、对照组于入组时分别评定Bech-Rafaelsen躁狂量表(BRMS)评分表并收集血浆,采用实时荧光定量聚合酶链式反应(PCR)技术检测血浆micro RNA-134及LIMK-1 m RNA的表达水平,最后对检测结果及BRMS评分进行统计分析。结果治疗前,患者组血浆micro RNA-134及LIMK-1 m RNA表达水平分别为(1.17±0.02)、(0.37±0.02)显著低于对照组的(1.46±0.04)、(0.46±0.01),差异有统计学意义(P<0.05);治疗1个月后,患者组血浆micro RNA-134、LIMK-1 m RNA表达水平分别为(1.36±0.07)、(0.52±0.01)较治疗前显著升高,差异有统计学意义(P<0.05)。患者组治疗前及治疗后血浆micro RNA-134表达水平与BRMS评分之间均存在负相关(r=-0.48、-0.39,P<0.05)。结论血浆micro RNA-134、LIMK-1 m RNA的表达水平和双相障碍躁狂发作有关,有可能作为双相躁狂的生物标记物。
文摘目的:观察百令胶囊联合达格列净治疗糖尿病肾病疗效及对Caspase-1mRNA、NLRP3炎症小体水平的影响。方法:采用随机数字表法将80例糖尿病肾病患者分成观察组和对照组。对照组予达格列净治疗,观察组同时联合百令胶囊治疗。经连续治疗3个月,比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、肾功能指标[肾小球滤过率(eGFR)、血肌酐(Scr)、24 h尿微量白蛋白]、NLRP3炎性小体、半胱氨酸蛋白酶1(Caspase-1)mRNA、炎性因子[肿瘤坏死因子(TNF-α)、白细胞介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)]水平变化,统计两组治疗总有效率,评价治疗安全性。结果:治疗后,两组FPG、2 h PG、HbA1c水平,Scr、eGFR、24 h尿微量白蛋白水平,Caspase-1mRNA、NLRP3炎症小体表达水平,TNF-α、IL-1β、hs-CRP水平均明显低于治疗前(P<0.05),且观察组治疗以上指标水平均低于对照组(P<0.05);观察组总有效率为92.5%,优于对照组(75.0%)(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:百令胶囊联合达格列净治疗糖尿病肾病疗效显著,能够有效控制血糖水平,减少24 h尿蛋白,改善患者肾功能,治疗机制可能与抑制炎症反应、降低NLRP3炎症小体水平有关。
基金Supported by the Wuhan Municipal Health Commission Medical Research Project-Youth Project(No.WZ20Q04).
文摘Objective The initiation and progression of lung carcinomas are critically regulated by long non-coding RNAs(lncRNAs).However,the role of lncRNAs in the pathways causing lung cancer remains unknown.Methods Cell morphology was regularly observed using an inverted phase-contrast microscope.Cell viability was assessed using CCK-8 according to the manufacturer’s instructions.Total RNA was retrotranscribed from each specimen using the RNAiso Plus Kit.The RT-PCR data were calculated using the Ct approach for comparison.Flow cytometric analyses were prepared by Click-iT™Plus TUNEL Assay for In Situ apoptosis detection,with Alexa Fluor^(TM)594 dye,as instructed.RNA immunoprecipitation assays were used to determine RNA concentration.Results Activated natural killer cells repeat and PH domain-containing protein 2 antisense RNA 1(AGAP2-AS1)levels in cancerous tissues were significantly correlated with cancerous tumor node metastasis(TNM)stage,with cancerous AGAP2-AS1 levels being higher in cancerous tissues than healthy tissues.Patients withelevated AGAP2-AS1 levels had considerably worse outcomes than those with reduced AGAP2-AS1 levels,regardless of the progression-free or overall survival.Functionally,AGAP2-AS1 downregulation represseslung cancer cell growth.AGAP2-AS1 elimination induces erastin-mediated ferroptosis in lung cancer cells.However,the ferritin inhibitor FERSINT-1 negated this result,whereas ERASTIN induced lung cancer cellmortality.After AGAP2-AS1 silencing,erastin-treated lung cancer cells showed a remarkable decrease inGSH levels.These results indicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via Recombinant Insulin Like Growth Factor Binding Protein 2(IGF BP2).Patients with elevated AGAP2-AS1 had considerably worse outcomes.Down-regulating AGAP2-AS1 was able to repress lung cancer cell growth and induce greater Erastin-mediated ferroptosis.Lungcancer cells treated with Erastin exhibited a remarkable decrease inglutathione(GSH)levels.The mechanical findingsindicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via the IGF2BP2.Conclusion We identified a novel effect of AGAP2-AS1 on TNM staging and the prognosis of patientswith lungcancer by modulating SLC7A11 mRNA stability and ferroptosis.